{
    "clinical_study": {
        "@rank": "104327", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Subjects with biochemical failure experience after primary treatment and have high-risk disease"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Subjects presenting with a medical diagnosis of castrations-resistant prostate cancer"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Subjects with an initial diagnosis of metastatic prostate cancer"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to describe patterns in disease management  and to describe\n      clinical outcomes, as well as to identify factors influencing physician treatment decisions\n      including reason(s) for treatment choices and trigger(s) for treatment changes and to\n      document healthcare resource utilization used to manage treatment-related complications."
        }, 
        "brief_title": "A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostrate Cancer and Men With Metastatic Prostate Cancer", 
        "completion_date": {
            "#text": "November 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostate Cancer", 
            "Metastatic Prostate Cancer", 
            "Castration-resistant Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Each subject will be followed from the time of enrollment for a minimum of 4 years and a\n      maximum of up to 6 years or until death, whichever comes first."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of prostate adenocarcinoma\n\n          -  Will receive active treatment for prostate cancer at the time of study entry, as\n             defined by one of the groups below:\n\n               -  Biochemical failure after initial curative-intent surgery (radical\n                  prostatectomy) or radiotherapy (external-beam radiation therapy, brachytherapy,\n                  or both) and a PSA doubling time of one year or less within 4 weeks of study\n                  entry; or\n\n               -  Newly diagnosed castration-resistant prostate cancer; or\n\n               -  Metastatic prostate cancer at initial diagnosis of prostate cancer and will\n                  receive active systemic therapy\n\n        Exclusion Criteria:\n\n          -  Prior treatment with systemic chemotherapy\n\n          -  Life expectancy of <1 year due to comorbidities\n\n          -  Participation in a clinical trial of an investigational therapy at study entry"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects will be selected from the offices of either a medical oncologist, radiation\n        oncologist, uro-oncologist, urologist, surgeon, or primary care physician."
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066961", 
            "org_study_id": "ONC-MA-1001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prostate cancer", 
            "metastatic prostate cancer", 
            "castration-resistant prostate cancer"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamilton", 
                    "country": "New Zealand", 
                    "state": "Waikato", 
                    "zip": "3204"
                }, 
                "name": "Waikato Urology Research Limited"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "New Zealand"
        }, 
        "number_of_groups": "3", 
        "official_title": "A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis", 
        "overall_contact": {
            "email": "gma_clinicaltrials.gov@astellas.com", 
            "last_name": "Astallas Global Medical Affairs, Inc.", 
            "phone": "224-205-8800"
        }, 
        "overall_official": {
            "affiliation": "Astellas Scientific & Medical Affairs, Inc.", 
            "last_name": "Senior Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Brazil: Associa\u00e7\u00e3o Fundo de Incentivo \u00e0 Pesquisa", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Peru: Instituto Nacional de Salud", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: Ministry of Health, Welfare and Sport", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Indonesia: National Agency of Drug and Food Control", 
                "Korea: Food and Drug Administration", 
                "New Zealand: Medsafe", 
                "Philippines : Food and Drug Administration", 
                "Singapore: Clinical Trials & Epidemiology Research Unit (CTERU)", 
                "Taiwan : Food and Drug Administration", 
                "Thailand: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Description of disease assessment methods, physician referral patterns and treatments", 
                "measure": "Patterns of disease management", 
                "safety_issue": "No", 
                "time_frame": "up to 72 months"
            }, 
            {
                "description": "Evidence of disease progression and development of symptomatic disease", 
                "measure": "Clinical outcomes", 
                "safety_issue": "No", 
                "time_frame": "up to 72 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reason/s for treatment choices and trigger/s for treatment changes", 
                "measure": "Factors influencing physician treatment decisions", 
                "safety_issue": "No", 
                "time_frame": "up to 72 months"
            }, 
            {
                "measure": "Documentation of healthcare resource utilization used to manage treatment-related complications", 
                "safety_issue": "No", 
                "time_frame": "up to 72 months"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Scientific & Medical Affairs, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}